miR-185 suppresses progression of Ewing’s sarcoma via inhibiting the PI3K/AKT and Wnt/β-catenin pathways
Authors Zhang S, Li D, Jiao G, Wang H, Yan T
Received 9 March 2018
Accepted for publication 19 August 2018
Published 9 November 2018 Volume 2018:11 Pages 7967—7977
Checked for plagiarism Yes
Review by Single-blind
Peer reviewers approved by Dr Cristina Weinberg
Peer reviewer comments 5
Editor who approved publication: Dr Jianmin Xu
Shuai Zhang,1 Dong Li,2 Guang-jun Jiao,1 Hong-liang Wang,1 Ting-bin Yan1
1Department of Orthopedics, Qilu Hospital of Shandong University, Jinan, Shandong Province, China; 2Department of Orthopedics, Shandong Provincial Hospital Affiliated to Shandong University, Jinan, Shandong Province, China
Background: miRNAs are confirmed to play essential roles in tumorigenesis and progression of cancers, including Ewing’s sarcoma. miR-185 has been reported to be downregulated in some tumors, whereas the role of miR-185 in Ewing’s sarcoma remains unclear.
Purpose: The objective of this study was to investigate the role of miR-185 in the progression and metastasis of Ewing’s sarcoma and explore the associated mechanism.
Materials and methods: Ewing’s sarcoma cell line RD-ES was transfected with pCMV-MIR-miR185 vector to upregulate the expression of miR-185. Cell Counting Kit 8 and colony formation assays were used to assess the effect of miR-185 on cell proliferation. The effect of miR-185 on cell migration and invasion was detected by transwell assay. Flow cytometry assay was performed to detect apoptosis rate of RD-ES cells. The protein levels of apoptosis-related proteins was determined using Western blot assay or immunohistochemistry assay. Dual-luciferase reporter assay was used to validate the regulation between miR-185 and its target gene.
Results: Upregulation of miR-185 caused significant inhibition on cell growth capacity, migration and invasion of Ewing’s sarcoma cell RD-ES. Besides, upregulation of miR-185 was observed to accelerate cell apoptosis in a mitochondrial pathway through regulating Bcl-2/Bax, Caspase 3, and Caspase 9 in Ewing’s sarcoma in vitro. Moreover, upregulation of miR-185 was found to suppress the PI3K/Akt/mTOR and Wnt/β-catenin pathways in RD-ES cells. Furthermore, we identified that E2F6 was a target gene for miR-185, and the suppression on cell proliferation caused by overexpression of miR-185 was significantly rescued by the upregulation of E2F6 in RD-ES cells.
Conclusion: miR-185 is involved in cell growth, motility and survival of Ewing’s sarcoma as a tumor suppressor via suppressing PI3K/Akt/mTOR and Wnt/β-catenin pathways and targeting E2F6.
Keywords: miR-185, PI3K/Akt/mTOR pathway, Wnt/β-catenin pathway, E2F6, Ewing’s sarcoma
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]